Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eleanor Malone

London, UK
Eleanor has been editor of Scrip Intelligence since 2014. She has more than 15 years’ experience writing specialist news and analysis for and about the biopharma industry. She holds an MA in modern languages from the University of Edinburgh. Based in London, she appears regularly on TV and radio and conference panels to discuss matters related to the industry.
Advertisement
Set Alert for Articles By Eleanor Malone

Latest From Eleanor Malone

Forge Therapeutics Excites Big Guns In Antibiotic World

Emerging Company Profile: Forge Therapeutics, which licensed intellectual property from the University of California San Diego in 2015, is aiming to have developed a novel class of antibiotic to treat Gram-negative superbugs, with its first drug candidate entering clinical development in 2020. The company has just announced an expanded research and discovery pact with Evotec in the UK, and boasts an impressive line-up of scientific advisors.

StartUps and SMEs Infectious Diseases

Interview: Joerg Moeller, Bayer Development Chief, On R&D Consolidation

Scrip caught up with Joerg Moeller, head of development at Bayer Pharmaceuticals, during the company's annual media day. Soon to take leadership of the German group's entire R&D organization, he talked about Bayer's R&D strategy and how the pharma industry will need to work with other healthcare stakeholders more collaboratively.

Research and Development Strategies Leadership

Bayer's Weinand Slams Silo Thinking, Short-Termism In Medicines Valuation

Healthcare decision makers need to get out of their short-termist, siloed thinking when it comes to medicines reimbursement if healthcare systems are to remain sustainable, argued Bayer Pharma chief Dieter Weinand at the company's annual pharma media day.

Pricing Debate Reimbursement

Busch Off to Shire, Moeller Up In Bayer R&D Consolidation; Xofigo Trial Turns Up Safety Issue

Bayer is combining its research and development organization in one unit. Discovery head Andreas Busch is leaving to join Shire while development head Joerg Moeller takes overall control. Meanwhile, Xofigo was linked to more fractures and deaths than the control arm in a prostate cancer trial.

Companies Leadership

Forendo Pharma: Tackling The Endometriosis Challenge

Emerging Company Profile: Finland's Forendo Pharma hopes an imminent improvement in diagnostic possibilities will eventually help it commercialize a drug for endometriosis, which it believes could enable more effective treatment of a disease that afflicts large numbers of women.

StartUps and SMEs Gynecology & Urology

Pharma Q3 Results Preview: J&J, Roche Set The Scene

Most of the big pharma companies will report their third-quarter results over the next three weeks. As usual, Johnson & Johnson and Roche will get out of the blocks early on. Scrip considers what to expect from the two front-runners, in the first of our regular financial results previews.

Sales & Earnings Biosimilars
See All
Advertisement
UsernamePublicRestriction

Register